Family Management’s Cardinal Health CAH Stock Holding History

Family Management’s Portfolio CAH Stock Details CAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23,134	Closed	-$3.63M	–	290
2025 Q3	$3.63M	Buy	23,134 +12	+0.1%	+$1.85K	0.5%	53
2025 Q2	$3.88M	Sell	23,122 -213	-0.9%	-$31.6K	0.58%	46
2025 Q1	$3.21M	Buy	+23,335	New	+$2.97M	0.53%	51

Other funds holding CAH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Family Management's CAH Position: Q4 2025 in Review

Family Management sold out of Cardinal Health (CAH) in Q4 2025, closing a stake of 23,134 shares — an estimated $3.63M sold.

Family Management first reported a position in CAH in Q1 2025 and held it in 3 quarters. The position peaked at $3.88M in Q2 2025. 1,410 funds tracked by Wall St. Rank hold CAH as of Q4 2025.

Family Management reported no remaining Cardinal Health position as of Q4 2025 after selling out during the quarter.
Family Management sold 23,134 Cardinal Health shares in Q4 2025, an estimated $3.63M.
Family Management first reported a position in Cardinal Health in Q1 2025 and held it in 3 quarters.
Family Management's Cardinal Health position peaked at $3.88M in Q2 2025.
1,410 funds tracked by Wall St. Rank held Cardinal Health as of Q4 2025.

Based on Family Management's 13F filing for Q4 2025, filed 17 Feb 2026.